ALMR — what changed in the latest 10-Q
A section-by-section comparison of ALMR's newest periodic SEC filing (10-K/10-Q) against the prior same-form filing: paragraphs added and removed per section, with verbatim excerpts. Purely a deterministic text diff — no similarity scores, no directional read, not investment advice.
Comparing 10-Q · 2026-08-11 vs the prior 10-Q · 2026-05-08
| Section | Outcome | Added | Removed | Minor | Unchanged |
|---|---|---|---|---|---|
| MD&A | Text added/removed | +26 | −11 | ~26 | 47 |
| Market risk (Item 3) | Text added/removed | 0 | 0 | ~1 | 0 |
| Controls & procedures | Text added/removed | 0 | 0 | ~1 | 3 |
| Legal proceedings | No paragraph-level changes | 0 | 0 | 0 | 1 |
| Risk factors | Text added/removed | +79 | −71 | ~47 | 389 |
Counts are paragraphs; added/removed means text added or removed vs the prior filing — no direction or judgement implied.
Not shown (absent or not faithfully extractable): Other information
Representative excerpts
Up to 5 excerpts of about 300 characters per section, quoted verbatim from the two SEC filings.
MD&A
Text added vs the prior filing · source: 10-Q · 2026-08-11
compensation-related costs and higher consulting costs associated with technology and product development. Compensation-related costs include a $0.6 million increase in stock-based compensation expense.
Our results of operations for each of the periods indicated are summarized in the table below:
Revenue was $55.5 million in the six months ended June 30, 2026 compared to $29.3 million in the six months ended June 30, 2025. Product revenue, which is comprised of instrument revenue and consumables revenue, increased by $23.4 million, or 110%, to $44.6 million in the six months ended June 30, 2…
Service and other revenue increased by $2.8 million, or 35%, to $10.9 million in the six months ended June 30, 2026, compared to $8.0 million in the six months ended June 30, 2025. The increase was primarily due to increased TAP services, including services to develop custom assays.
Cost of revenue was $23.3 million in the six months ended June 30, 2026 compared to $14.3 million in the six months ended June 30, 2025. Cost of product revenue increased by $7.8 million, or 66%, to $19.7 million in the six months ended June 30, 2026, compared to $11.9 million in the six months ende…
Text removed vs the prior filing · source: 10-Q · 2026-05-08
Comparison of the three months ended March 31, 2026 and 2025
personnel headcount, which resulted in higher compensation-related costs and higher consulting costs associated with technology and product development.
As of March 31, 2026, we had $64.6 million in unrestricted cash and cash equivalents, $4.9 million in restricted cash, and access to a total of up to $50.0 million of unused committed term loan facility and undrawn revolver balance with Silicon Valley Bank, a division of First Citizens Bank (“SVB”),…
Since inception, our principal sources of liquidity have been proceeds from the sale of our equity securities, revenue from sales of our products and services, and, to a lesser extent, borrowings from loan facilities. As of March 31, 2026, we had an accumulated deficit of $190.1 million, attributabl…
On July 11, 2024, we entered into a loan and security agreement with SVB which permitted us to draw term loan advances of up to an aggregate sum of $35.0 million under Tranche A and Tranche B. This amount remained undrawn until the agreement was amended in September 2025. On September 19, 2025, we e…
Risk factors
Text added vs the prior filing · source: 10-Q · 2026-08-11
We and/or our third-party manufacturing partner may be unable to consistently manufacture our products to the necessary specifications or in quantities necessary to meet demand at an acceptable cost or at an acceptable performance level.
qualifications. Our ability to increase our manufacturing capacity at our Fremont, California is complicated by the use of our validated equipment model that is not readily available from third-party manufacturer.
Additionally, we have not qualified secondary sources for all materials or components that we source through a single
specifications and instructions. If any of these issues occur, we may also incur significant costs, the attention of our key personnel could be diverted or other significant customer relations problems may arise.
expenses related to our facilities and real estate, including costs and/or disruptions related to tenant improvements;
Text removed vs the prior filing · source: 10-Q · 2026-05-08
We and/or our third-party manufacturing partner may be unable to consistently manufacture our products to the
necessary specifications or in quantities necessary to meet demand at an acceptable cost or at an acceptable performance level.
of our validated equipment model that is not readily available from third-party manufacturer.
Additionally, we have not qualified secondary sources for all materials or components that we source through a single supplier and we cannot assure investors that the qualification of a secondary supplier will prevent future supply issues.
key personnel could be diverted or other significant customer relations problems may arise.
How to read Risk Factors (Item 1A) in a 10-Q
A 10-Q risk-factor section usually takes one of three forms; this page classifies it as one of:
- Pointer — the filer states there have been no material changes and points back to the annual 10-K risk factors; there is no own risk text to compare this quarter.
- Partial update — the filer carves out specific updated risks ("except as set forth below"); the excerpts show exactly what is new this quarter.
- Restated in full — the quarter carries the complete risk-factor text. When the prior quarter was only a pointer there is no prior full text to diff against, so the page flags the section as restated instead.
This describes the filing structure only — it is never a judgement on whether risk went up or down.
Source: text-level diff of the two SEC EDGAR filings · deterministic (no AI-generated content) · for reference only · not investment advice